AUTO 1 NG
Alternative Names: AUTO-1-NG; AUTO1 22; AUTO1/22Latest Information Update: 28 Jan 2024
At a glance
- Originator Autolus
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Precursor cell lymphoblastic leukaemia-lymphoma
Most Recent Events
- 28 Jan 2024 No recent reports of development identified for phase-I development in Precursor-cell-lymphoblastic-leukaemia-lymphoma(In adolescents, In children, In infants, In neonates, In adults) in United Kingdom (Parenteral)
- 10 Dec 2022 Efficacy and adverse events data from phase I CARPALL trial in Precursor cell lymphoblastic leukaemia lymphoma presented at the 64th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2022)
- 21 Aug 2022 Efficacy and adverse events data from phase I CARPALL trial in Precursor cell lymphoblastic leukaemia lymphoma presented at the 27th Congress of the European Haematology Association (EHA-2022)